Regarding the AJCC stage, significant differences were also observed, with the highest percentage of stage I/II tumors in luminal A (77.3%) and TN (77.1%) subtypes, whereas luminal B (Her2/neu+) and patients with Her2/neu tumors showed the largest prevalence of stage III cancers (35.0% and 35.6%, respectively). This evidence concerns the gene ERBB2 and cancer.